Compare Vanguard Emerging Markets Stock Index Fund ETF (VWO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Emerging Markets Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Emerging Markets Stock Index Fund ETF trades at $60.4, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VWO | XBI | |
|---|---|---|
52-Week High | $61.24 | $164.28 |
52-Week Low | $51.20 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VWO, the Vanguard FTSE Emerging Markets ETF, trades at $60.41, up 0.13% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The fund's low expense ratio of 0.06% and focus on emerging markets attract institutional inflows, as seen in recent 13F filings. Recent news highlights strong capital flows into emerging market ETFs and comparisons with peers on cost and diversification.
The outlook for VWO is supported by record inflows and favorable expense ratios, but risks include concentrated exposure to developing economies and currency volatility. Analyst sentiment is generally positive due to diversification benefits and cost efficiency, though geopolitical and economic uncertainties in emerging markets pose significant headwinds for sustained growth.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
